Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
133 results about "Cholesterol blood" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cholesterol is a fat (also called a lipid) that your body needs to work properly. Too much bad cholesterol can increase your chance of getting heart disease, stroke, and other problems. The medical term for high blood cholesterol is lipid disorder, hyperlipidemia, or hypercholesterolemia.
Bioactive Complexes Compositions and Methods of Use Thereof
InactiveUS20070085059A1Enhanced soluble complexesGood fluidityCosmetic preparationsNervous disorderDiseaseCholesterol blood
A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, Omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides. The composition may optionally be further utilized for the prevention of hypercholesterolemia, bone (and teeth) mineral loss, treatment of mental health diseases, heart health, additional nutritional supplementation, and treatment of additional medical conditions.
Owner:TEXAS A&M UNIVERSITY
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ActiveUS20100152118A1Widen the optionsOrganic active ingredientsMetabolism disorderCyclaseCoronary artery disease
This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
Owner:BAUSCH HEALTH IRELAND LTD
Methods for treating hypercholesterolemia
InactiveUS8093222B2Reduction of ldl c levelLower Level RequirementsSugar derivativesMetabolism disorderMedicineCholesterol blood
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and / or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
Owner:IONIS PHARMA INC
Nanoemulsion compositions and methods of use thereof
InactiveUS20070085058A1Improve bioavailabilityEnhanced soluble complexesCosmetic preparationsToilet preparationsAdditive ingredientCholesterol blood
A nanoemulsion composition having enhanced oxidative stability, emulsion stability, and health benefits. The composition may include individual ingredients or a synergistic blend of non-reducing sugars, sugar polyols, medium-chain triglycerides, polysaccharides, polyphenols, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides. The composition may optionally be further utilized for the prevention of hypercholesterolemia or bone (and teeth) mineral loss.
Owner:PETTY BLAKE
Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
ActiveUS8399441B2Lower Level RequirementsImprove suppression propertiesOrganic active ingredientsMetabolism disorderLipid formationMetabolite
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases
This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
Owner:BAUSCH HEALTH IRELAND LTD
Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
InactiveUS20050267091A1BiocideHydroxy compound active ingredientsCholesterol bloodCoronary heart disease
A composition is provided which contains policosanol and niacin and / or niacin derivatives and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, Lp(a), triglycerides, coronary heart disease (heart attacks and strokes), inflammation, immunoregulatory diseases, cardiovascular diseases, deep vein thrombosis, anxiety, depression and / or neurodegenerative disorders, and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and niacin and / or niacin derivatives which together effectively lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to niacin and / or niacin derivatives.
Owner:WYETH LLC
Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
InactiveUS20060020031A1Reduce and prevent hypercholesterolemic diseaseBiocideHydroxy compound active ingredientsCholesterol bloodCoronary heart disease
A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and / or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and / or neurodegenerative disorders, and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.
Owner:WYETH
Antioxidant compositions and methods of use thereof
ActiveUS7118688B2Preventing bone mineral lossImproves antioxidant activityCosmetic preparationsToilet preparationsCholesterol bloodAdditive ingredient
Owner:TEXAS A&M UNIVERSITY
Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
Owner:VARADHACHARY ATUL +3
Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor
Owner:LEK PHARMA & CHEM
Therapeutic compositions
InactiveUS6946151B2Lower blood sugar levelsSlow onsetBiocideOrganic active ingredientsDiseaseAntioxidant
An oral composition, suitable as a hypoglycemic agent, includes an isolate from the leaves of Gymnema sylvestre, having a specified molecular weight. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient can be regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, in combination with a non-metabolizable, water-swellable polysaccharide such as the exudate of Sterculia urens, and a water-soluble polysaccharide such as guar gum. Optionally, the present oral compositions can include a physiologically acceptable calcium source, a physiologically acceptable metal carbonate salt, a physiologically acceptable chromium salt, and / or a physiologically acceptable vanadium compound. In addition, antioxidants such as ascorbic acid, cholecalciferol, d-α-tocopherol, the carotenoids, lycopene, lutein, and the like, can be included as well. The present compositions are useful for amelioration of cholesterolemia, obesity, chronic complications of diabetes and prophylaxis for patients predisposed to the foregoing.
Owner:AYURVEDIC LIFE INT LLC
2-oxochromene derivatives
To provide a novel LXRβ agonist that is useful as a preventative and / or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.[Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.
Owner:KOWA CO LTD
Methods for treating hypercholesterolemia and atherosclerosis
InactiveUS20090312297A1Restore glucose homeostasisIncrease insulin sensitivityBiocideMetabolism disorderDyslipidemiaCholesterol blood
The invention provides compounds and pharmaceutical compositions that can be used to treat or prevent atherosclerosis, stroke, and other ischemic vascular diseases, dyslipidemia and hypercholestcrolemia and prevent complications of these conditions. Agents in accordance with the invention include; tauroursodeoxycholic acid (TUDCA), and analogs and derivatives thereof; 4-phenyl butyric acid (PBA), and analogs and derivatives thereof; and trimethyl N-oxide (TMAO), and analogs and derivatives thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Methods for modulating metabolism
InactiveUS7759398B2Prevention delay in developmentHigh expressionBiocideSenses disorderCysteamineBiological condition
The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and / or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and / or treat or prevent the onset of diabetes-associated complications.
Owner:OMEGA BIO PHARMA I P 3
Bioactive complexes compositions and methods of use thereof
InactiveUS7780873B2Enhanced soluble complexesGood fluidityCosmetic preparationsNervous disorderDiseaseCholesterol blood
Owner:TEXAS A&M UNIVERSITY
Hyperlipidemia Treatment Agent
To provide a cholesterolemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering serum cholesterol. And to provide a triglyceridemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering triglycerides.
Owner:TOA PHARMA
Pharmaceutical compositions of atorvastatin
The present invention provides stable pharmaceutical compositions comprised of atorvastatin and sodium bicarbonate or L-arginine. The compositions are prepared as bulk drug compositions and also as oral dosage units, such as tablets or capsules. The compositions are useful for preparation of monolithic and bi-layer tablets containing atorvastatin as the only active agent or combined with one or more additional active agents. The compositions are useful for treating hypercholesterolemia and related conditions.
Owner:MERCK SHARP & DOHME CORP
Methods for reducing cardiovascular risk
InactiveUS20150284473A1Reduce cardiovascular riskReduce riskAntibody ingredientsCardiovascular disorderCholesterol bloodMaximum tolerated dose
The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.
Owner:SANOFI BIOTECH +1
Compositions and methods for cardiovascular disease
InactiveUS20140038953A1Reduce riskLower Level RequirementsBiocideOrganic chemistryMedicineSecondary hyperlipidemia
The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to reduce circulating levels of ApoB-100 or LDL. These compounds may also be used to treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
Owner:THE GENERAL HOSPITAL CORP
Ezetimibe orally disintegrating tablet and preparation method thereof
ActiveCN104490833ASimple preparation processEasy to takeOrganic active ingredientsMetabolism disorderSolubilityOlder people
The invention discloses an orally disintegrating tablet which takes ezetimibe as an effective ingredient and has an effect of treating hypercholesteremia and a preparation method thereof. Regarding the problem of poor water solubility of ezetimibe, under the condition that a surfactant is not used, on the one hand, the grain diameter is reduced by adopting a micronization technology or the disintegrating tablet is prepared into a solid dispersion so as to improve the solubility, and on the other hand, the tablet can be quickly disintegrated in the oral cavity by means of the formula, so that the disintegrating tablet can be dissolved quickly. Furthermore, the invention aims to provide the ezetimibe orally disintegrating tablet which is simple in preparation process, convenient to take, quick in response and remarkable in curative effect; the orally disintegrating tablet can be taken without drinking water, can be quickly disintegrated in tens of seconds in the oral cavity, and is especially suitable for old people, children and patients with swallowing difficulty.
Owner:WUHAN WUYAO SCI & TECH
Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
ActiveUS20100273761A1Improve suppression propertiesDecrease lipid biosynthesisOrganic active ingredientsAntipyreticLipid formationMetabolite
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Extract of effective part of sibiraea augustata(rehd.) hand-mazz for preventing adiposity and lowering hyperlipoidemia, preparation method and application thereof
ActiveCN101732441ABroaden the use of medicineIncrease viscosityMetabolism disorderPlant ingredientsCholesterol bloodEthyl acetate
The invention relates to the field of traditional Chinese medicines, in particular to an extract of the effective part of sibiraea augustata(rehd.) hand-mazz for preventing adiposity and lowering hypercholesteremia, a preparation method and an application thereof. According to the prevention of the adiposity in the invention, the extract of the effective part of the sibiraea augustata(rehd.) hand-mazz is obtained by the method comprising the following steps: (1) washing and pulverizing; (2) leaching by water to obtain a total water leaching extract; (3) dissolving the total extract by methanol or ethanol; (4) extracting by chloroform or methylene chloride; and (5) extracting a water solution after being degreased by the chloroform or the methylene chloride by ethyl acetate, decompressing and concentrating to obtain the effective part. The invention provides the effective part of an ethyl acetate extract in the extract of the sibiraea augustata(rehd.) hand-mazz, and the ethyl acetate extract can prevent the adiposity and treat the hypercholesteremia, can suppress the multiplication and the differentiation of precursor fat cells and acts as the function of preventing obesity.
Owner:BEIJING NORMAL UNIVERSITY
Bmp inhibitors and methods of use thereof
InactiveUS20160115167A1Reduce riskLower Level RequirementsAntibacterial agentsOrganic active ingredientsCholesterol bloodApoptosis
The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and / or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
Owner:THE GENERAL HOSPITAL CORP +1
Combination therapy for treating hypercholesterolemia
The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.
Owner:GENZYME CORP
Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
InactiveUS20060135785A1Improve bioavailabilityImprove stabilityOrganic chemistryMetabolism disorderCholesterol bloodEnantiomer
Owner:PIERRE FABRE MEDICAMENT SAS
Traditional Chinese medicine oral decoction for treating coronary heart disease
InactiveCN102114085AIncrease elasticityPrevent atherosclerosisPharmaceutical delivery mechanismCardiovascular disorderMedicinal herbsDisease
The invention relates to a medicine for treating coronary heart disease, particularly relates to a traditional Chinese medicine oral decoction for treating coronary heart disease. The traditional Chinese medicine oral decoction is prepared from traditional Chinese medicinal herbs as raw materials. The traditional Chinese medicine oral decoction is prepared from the following raw materials according to the parts by weight (unit: gram): 20-30g of milkvetch root, 10-20g of Dan-shen root, 10-20g of szechwan lovage rhizome, 5-15g of red peony root, 5-15g of pilose asiabell root, 5-15g of Chinese angelica root, 10-20g of safflower and 5-10g of licorice root. The traditional Chinese medicinal herbs are compounded to benefit mutually. The traditional Chinese medicine oral decoction provided by the invention has the effects of promoting blood circulation, dredging meridians, loosening bowel to relieve constipation, removing heat from blood, dispelling blood stasis, relieving swelling, invigorating qi, consolidating superficial resistance, promoting urination, expelling toxic materials, promoting pus discharge, promoting wound healing, promoting tissue regeneration, regulating immunity, inhibiting bacteria, resisting cancer, lowering blood pressure and regulating blood lipid, so as to effectively repair cells, eliminate waste in blood, gradually dissolve cholesterol and blood fat on the walls of blood vessels, eliminate atherogenic blood lipid precipitation and improve blood vessel elasticity. The oral decoction takes remarkable effect during the course of treating coronary heart disease. The oral decoction can be used for treating both principal and secondary aspect of disease, is economical and practical, and has the advantages of small adverse effect, remarkable curative effect, self operation and simple operation method.
Owner:李银春
PCSK9 antagonist
InactiveCN105001336AMetabolism disorderAntibody ingredientsVery low-density lipoproteinCholesterol blood
The present invention relates to the technical field of monoclonal antibodies, particularly to a PCSK9 antagonist. The present invention further provides a method for obtaining the antibodies, uses of the antibodies to reduce the low density lipoprotein (LDL)-cholesterol level, and / or a treatment method for treatment and / or prevention of cardiovascular diseases (including hypercholesterolemia).
Owner:上海复旦张江生物医药股份有限公司
Pharmaceutical compositions of atorvastatin
A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and / or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.
Owner:WARNER-LAMBERT CO
Double-layer tablet containing ezetimibe and rosuvastatin and preparation method thereof
ActiveCN103585157AImprove the quality of lifeReduce adverse reactionsOrganic active ingredientsMetabolism disorderSolubilityAdditive ingredient
The invention relates to a double-layer tablet which contains ezetimibe and rosuvastatin serving as effective components and has a lipid-lowering effect and a preparation method thereof. Aiming at the problems poor water solubility of ezetimibe, instability of rosuvastatin to acid and oxygen and the like, the method adopts a micronization technology to improve the dissolution rate of ezetimibe and adopts an anti-oxidizing agent and a double-layer tabletting technology to improve the stability of rosuvastatin in a human body, further, ingredients of a medicine is enabled to take effect sufficiently, and the best synergistic effect is achieved; and a compound preparation agent is mainly applied to treatment of diseases relative to hypercholesteremia.
Owner:WUHAN WUYAO SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com